Other languages Ceapro Inc.

Equities

CZO

CA1499071076

Market Closed - Toronto S.E. Other stock markets 03:08:52 2024-04-26 pm EDT			5-day change	1st Jan Change
0.26 ^CAD	+8.33%		+6.12%	+36.84%

Mar. 28	Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	MT
Mar. 28	Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	Mar. 27
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co	Dec. 14
Ceapro Inc. Announces Dosing of First Patients In Phase 1-2a Study of Avenanthramides	Dec. 13
Ceapro Inc. Announces Commencement of Patient Dosing in its Phase 1-2a Study Evaluating its Product, Avenanthramides, for Potential Applications in Managing Conditions Related to Inflammation	Dec. 13
Ceapro Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 29
Ceapro Inc. Initiates Phase 1-2a Study Assessing Avenanthramides For Potential Applications in Inflammation Based Diseases	Nov. 27
Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases	Nov. 27
Ceapro Inc. Announces the Signing of A Technical Collaboration with NATEX Prozesstechnologie Gmbh to Accelerate the Scale-Up of Its Proprietary PGX Technology Towards Commercial Level	Nov. 07
Ceapro Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29
Ceapro Extends International Supply and Distribution Agreement with German Provider of Active Ingredients, Symrise	23-08-25
Ceapro Inc. Extends Exclusive International Supply and Distribution Agreement with Symrise	23-08-25
Ceapro Inc. Announces Next Phase of Research Collaboration with the Angiogenesis Foundation	23-07-18
Ceapro Inc. Announces Resignation of Glenn Rourke as A Director	23-06-07
Ceapro Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases	23-05-23
Ceapro on Findings That Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing, Tissue Regeneration	23-05-03
Ceapro Inc. Announces Positive Results from Research Collaboration with the Angiogenesis Foundation Conducted with Researchers At the University of Arizona	23-05-03
Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations, Effective May 1, 2023	23-04-27
Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-12
Ceapro Says Data from Research Collaboration with Angiogenesis Foundation to be Presented at Wound Healing Society Meet	23-03-08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Ceapro Inc.

Equities

CZO

CA1499071076

Other languages

Filters